



Twist Bioscience Chief Technology Officer Presented at Praesens Foundation Future Health Threats Initiative 2019

January 30, 2019

SAN FRANCISCO--(BUSINESS WIRE)--Jan. 30, 2019-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced that Bill Peck, Ph.D., chief technology officer, participated in the Future Health Threats Initiative 2019, a conference designed to encourage public-private cooperation to strengthen health security in Africa. The workshop was focused on bio-IT and genomics. The conference was held January 28-29 in Leuven, Belgium.

About the Praesens Foundation and the Future Health Threats Initiative

The Praesens Foundation is operating at the intersection of global health technology innovation and social impact. It has the privilege to collaborate with a broad network of professionals who are passionate about what they do and can act as a rallying point for impactful initiatives. Driven by its field experiences in Africa and aiming for tangible outcomes, it is uniquely positioned to have hosted and coordinated this meeting by creating a working space and interface where individuals and organizations could exchange ideas freely, pool assets and resources and agree on how to execute upon a common vision to strengthen surveillance, disease intelligence, and health information exchange. This will be in support of Africa CDC's mission that envisions a safer, healthier, integrated and stronger Africa, whereby Member States are capable of effectively responding to outbreaks of infectious diseases and other public health threats. The Future Health Threats Initiative is championing interdisciplinary problem-solving and the Praesens Foundation aims to bring together the best in class, who are fostering innovation, digital transformation and bio-informatics in order to have a better overall picture of health and information at hand.

About Twist Bioscience Corporation

Twist is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of its platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on [Twitter](#) | [Facebook](#) | [LinkedIn](#)

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190130005189/en/>

Source: Twist Bioscience Corporation

Investor Contact:

Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com

Media Contact:

Angela Bitting
925- 202-6211
media@twistbioscience.com